| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC3022 |
| Trial ID | NCT05360238 |
| Disease | Diffuse Large B-Cell Lymphoma | Small Lymphocytic Lymphoma | B-Cell Lymphoma | B-Cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia |
| Altered gene | CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | MB-106 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL |
| Year | 2022 |
| Country | United States |
| Company sponsor | Mustang Bio |
| Other ID(s) | MB106-CD20-001|1R44CA265616-01 |
| Cohort 1 | |||||||||||
|
|||||||||||